MedPharm Ltd, a world-leading contract developer of topical and transdermal pharmaceutical products, is opening a new location in Raleigh-Durham, North Carolina that will expand its CDMO services in topical and transdermal delivery.
Doubling its existing footprint, the facility will support process development, clinical and small-scale commercial manufacturing for semi-solid and liquid pharmaceutical products.
This new site, located within a few miles of MedPharm’s current Center of Excellence for topical and transdermal development, gives MedPharm’s clients the opportunity to manufacture clinical batches and commercial scale products in the US.
“MedPharm’s investment in this facility is a clear demonstration of our continued commitment to a global vision by expanding client services downstream into commercial manufacturing’ stated Eugene Ciolfi, MedPharm’s President and CEO.
“MedPharm’s newest facility is an extension of our development services and will also support our client base with their clinical and commercial pipelines needs for topical and transdermal products globally.”
The facility is designed to meet all FDA, EMA and GMP requirements with state-of-the art design, operational support systems, technology and resource management.
About MedPharm
MedPharm is the world’s leading global contract provider of topical and transdermal product design and formulation development services. MedPharm’s expertise reduces risk and accelerates development timelines for proprietary pharmaceutical and generic customers through their unique, cost-effective and industry-leading performance testing models.
Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations MedPharm is recognized for their scientific rigor by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK with over 20 years of experience developing topical products.
